

# ORGANOGENESIS



## Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

February 8, 2024

CANTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2023 financial results will be reported after the market closes on Thursday, February 29th.

Management will host a conference call at 5:00 p.m. Eastern Time on February 29th to discuss the results of the quarter and fiscal year, and provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast [here](#), or access the teleconference [here](#). The live webcast can also be accessed via the company's website at [investors.organogenesis.com](https://investors.organogenesis.com). The webcast will be archived on the company website for approximately one year.

### About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit [www.organogenesis.com](http://www.organogenesis.com).

Investor Inquiries: ICR Westwicke Mike Piccinino, CFA [OrganolR@westwicke.com](mailto:OrganolR@westwicke.com) Press and Media Inquiries: [Organogenesiscommunications@organo.com](mailto:Organogenesiscommunications@organo.com)